Search

Your search keyword '"Revlimid (Medication)"' showing total 1,720 results
Start Over Descriptor "Revlimid (Medication)"
1,720 results on '"Revlimid (Medication)"'

1. Half Year 2025 Dr Reddy's Laboratories Ltd Earnings Call - Final

Subjects
Dr. Reddy's Laboratories Ltd., Financial statements, Pharmaceutical industry, Business, Revlimid (Medication)
Abstract

Presentation OPERATOR: Ladies and gentlemen, good day and welcome to the quarter two FY25 earnings conference call of Dr. Reddy's Laboratories Limited. (Operator Instructions) Please note that this conference is [...]

Published
2024

2. Q3 2024 BristolMyers Squibb Co Earnings Call - Final

Subjects
Bristol-Myers Squibb Co., Investment analysis, Business, Revlimid (Medication), Opdivo (Medication), Opdualag (Medication), Breyanzi (Medication), Sotyktu (Medication)
Abstract

Presentation OPERATOR: Good day, and welcome to the Bristol-Myers Squibb third-quarter 2024 earnings conference call. (Operator Instructions) Please note this event is being recorded. I would now like to turn [...]

Published
2024

3. Event Brief of Q3 2024 Bristol-Myers Squibb Co Earnings Call - Final

Subjects
Bristol-Myers Squibb Co. -- Conferences, meetings and seminars, Investment analysis -- Conferences, meetings and seminars, Financial markets -- Conferences, meetings and seminars, Chief operating officers -- Conferences, meetings and seminars, Chairpersons -- Conferences, meetings and seminars, Business, Revlimid (Medication), Opdivo (Medication), Opdualag (Medication)
Abstract

CORPORATE PARTICIPANTS . Chuck Triano - Bristol-Myers Squibb Co,Senior Vice President of Investor Relations . Christopher Boerner - Bristol-Myers Squibb Co,Chairman of the Board, Chief Executive Officer, Chief Operating Officer [...]

Published
2024

4. Event Brief of Q3 2024 Bristol-Myers Squibb Co Earnings Call - Final

Subjects
The Goldman Sachs Group Inc. -- Conferences, meetings and seminars, Bristol-Myers Squibb Co. -- Conferences, meetings and seminars, Investment analysis -- Conferences, meetings and seminars, Financial markets -- Conferences, meetings and seminars, Investment banks -- Conferences, meetings and seminars, Chief operating officers -- Conferences, meetings and seminars, Chairpersons -- Conferences, meetings and seminars, Pharmaceutical industry -- Conferences, meetings and seminars, Business, Revlimid (Medication), Opdivo (Medication)
Abstract

CORPORATE PARTICIPANTS . Chuck Triano - Bristol-Myers Squibb Co,Senior Vice President of Investor Relations . Christopher Boerner - Bristol-Myers Squibb Co,Chairman of the Board, Chief Executive Officer, Chief Operating Officer [...]

Published
2024

5. Q3 2024 BristolMyers Squibb Co Earnings Call - Final

Subjects
Bristol-Myers Squibb Co., Investment analysis, Pharmaceutical industry, Business, Revlimid (Medication), Opdivo (Medication), Breyanzi (Medication)
Abstract

Presentation OPERATOR: Good day, and welcome to the Bristol-Myers Squibb third-quarter 2024 earnings conference call. (Operator Instructions) Please note this event is being recorded. I would now like to turn [...]

Published
2024

6. Q1 2025 Natco Pharma Ltd Earnings Call - Final

Subjects
Natco Pharma Ltd. -- International economic relations, Pharmaceutical industry -- International economic relations, Business, Revlimid (Medication)
Abstract

Presentation OPERATOR: Ladies and gentlemen, good day, and welcome to the Natco Pharma Limited Q1 FY25 post-results earnings conference call hosted by Batlivala & Karani Securities India Private Limited. (Operator [...]

Published
2024

7. Q1 2025 Aurobindo Pharma Ltd Earnings Call - Final

Subjects
United States. Food and Drug Administration, Business, Revlimid (Medication)
Abstract

Presentation OPERATOR: Welcome to Aurobindo Pharma Q1 FY25 earnings call. (Operator Instructions) Please note that this conference is being recorded. I now hand the conference over to management for opening [...]

Published
2024

8. Q1 2025 Zydus Lifesciences Ltd Earnings Call - Final

Subjects
United States. Food and Drug Administration, Business, Revlimid (Medication)
Abstract

Presentation OPERATOR: Good afternoon, everyone. Welcome to Zydus Lifesciences Limited quarter-one FY25 earnings conference call. (Operator Instructions) Please note that this conference is being recorded. And I now hand over [...]

Published
2024

9. Q2 2024 Teva Pharmaceutical Industries Ltd Earnings Call - Final

Subjects
Teva Pharmaceutical Industries Ltd., Pharmaceutical industry, Business, Simlandi (Medication), Revlimid (Medication), Ajovy (Medication), Austedo (Medication), Victoza (Medication)
Abstract

Presentation OPERATOR: Hello. And welcome to the Teva Pharmaceuticals Industries Limited Q2 2024 earnings call. My name is Alex. And I'll be coordinating the call today. (Operator Instructions) I'll now [...]

Published
2024

10. Event Brief of Bristol-Myers Squibb Co at UBS Virtual Targeted Protein Degradation Day - Final

Subjects
Bristol-Myers Squibb Co. -- Conferences, meetings and seminars, UBS Group AG -- Conferences, meetings and seminars, Executives -- Conferences, meetings and seminars, Proteolysis -- Conferences, meetings and seminars, Investment banks -- Conferences, meetings and seminars, Pharmaceutical industry -- Conferences, meetings and seminars, Business, Revlimid (Medication)
Abstract

CORPORATE PARTICIPANTS . Robert Plenge - Bristol-Myers Squibb Co,Executive Vice President, Chief Research Officer, Head of Research, Member of the Leadership Team CONFERENCE CALL PARTICIPANTS . Trung Huynh - UBS [...]

Published
2024

11. BristolMyers Squibb Co at UBS Virtual Targeted Protein Degradation Day - Final

Subjects
Bristol-Myers Squibb Co., UBS Group AG, Proteolysis, Investment banks, Pharmaceutical industry, Business, Revlimid (Medication)
Abstract

Presentation OPERATOR: Welcome to the UBS call. Mr. Trung Huynh, you may begin. TRUNG HUYNH, ANALYST, UBS GROUP AG: Good morning, all. So welcome back from our short break. My [...]

Published
2024

12. Q4 2024 Natco Pharma Ltd Earnings Call - Final

Subjects
Natco Pharma Ltd. -- International economic relations, Pharmaceutical industry -- International economic relations, Business, Revlimid (Medication)
Abstract

Presentation OPERATOR: Ladies and gentlemen, good day, and welcome to the Natco Pharma Q4 and FY24 earnings conference call. Hosted by Batlivala & Karani Securities India Private Limited. (Operator instructions) [...]

Published
2024

13. Full Year 2024 Cipla Ltd Earnings Call - Final

Subjects
United States. Food and Drug Administration, Cipla Ltd. -- Company sales and earnings, Pharmaceutical industry -- Company sales and earnings, Company earnings/profit, Business, Revlimid (Medication)
Abstract

Presentation OPERATOR: Ladies and gentlemen, good day, and welcome to Cipla Limited Q4 FY '24 Earnings Conference Call. (Operator Instructions) Please note that this conference is being recorded. I now [...]

Published
2024

14. LATEST COMPANY NEWS

Subjects
United States. Food and Drug Administration -- Officials and employees, GSK PLC -- Forecasts and trends -- Officials and employees, Pfizer Inc. -- Officials and employees -- Forecasts and trends, Seagen Inc. -- Forecasts and trends -- Officials and employees, Roche Holding AG -- Forecasts and trends -- Officials and employees, Cardiovascular agents -- Forecasts and trends, Biotechnology industry -- Forecasts and trends -- Officials and employees, B cells -- Forecasts and trends, Cancer -- Care and treatment, Pharmaceutical industry -- Forecasts and trends -- Officials and employees, Market trend/market analysis, Business, international, Association of the British Pharmaceutical Industry -- Officials and employees, European Union -- Officials and employees, Camzyos (Medication), Revlimid (Medication), Verzenio (Medication), Mounjaro (Medication), Yervoy (Medication), Paxlovid (Medication), Opdivo (Medication), Breyanzi (Medication)
Abstract

Reuters - Bristol Myers earnings beat expectations, driven by sales of older drugs - 31/10/2024 Bristol Myers Squibb (BMY.N), opens new tab reported a higher-than-expected third-quarter profit on Thursday, citing [...]

Published
2024

15. Event Brief of Q1 2024 Bristol-Myers Squibb Co Earnings Call - Final

Subjects
The Goldman Sachs Group Inc. -- Conferences, meetings and seminars -- International economic relations, Bristol-Myers Squibb Co. -- International economic relations -- Conferences, meetings and seminars, Investment analysis -- Conferences, meetings and seminars, Investment banks -- International economic relations -- Conferences, meetings and seminars, Chairpersons -- Conferences, meetings and seminars, Pharmaceutical industry -- Conferences, meetings and seminars -- International economic relations, Business, Abecma (Medication), Camzyos (Medication), Revlimid (Medication), Opdualag (Medication), Breyanzi (Medication), Sotyktu (Medication)
Abstract

CORPORATE PARTICIPANTS . Adam Lenkowsky - Bristol-Myers Squibb Company,Executive VP, Chief Commercialization Officer & Head of U.S. Oncology . Christopher S. Boerner - Bristol-Myers Squibb Company,CEO & Chairman . David [...]

Published
2024

16. Q1 2024 BristolMyers Squibb Co Earnings Call - Final

Subjects
Bristol-Myers Squibb Co. -- International economic relations, Investment analysis, Pharmaceutical industry -- International economic relations, Business, Abecma (Medication), Camzyos (Medication), Revlimid (Medication), Opdivo (Medication), Opdualag (Medication), Breyanzi (Medication), Sotyktu (Medication)
Abstract

Presentation OPERATOR: Welcome to the Bristol-Myers Squibb First Quarter 2024 Earnings Conference Call. (Operator Instructions) Please note, today's event is being recorded. I would now like to turn the conference [...]

Published
2024

17. Q4 2024 Zydus Lifesciences Ltd Earnings Call - Final

Subjects
Business, Revlimid (Medication), Asacol (Medication)
Abstract

Presentation OPERATOR: Welcome to Zydus Lifesciences Limited quarter four FY24 earnings conference call. (Operator Instructions) Please note that this conference is being recorded. I now hand the conference over to [...]

Published
2024

18. Q3 2024 Natco Pharma Ltd Earnings Call - Final

Subjects
Natco Pharma Ltd. -- International economic relations, Pharmaceutical industry -- International economic relations, Business, Revlimid (Medication)
Abstract

Presentation OPERATOR: Ladies and gentlemen, good day, and welcome to the Natco Pharma Q3 FY24 post-results earnings conference call hosted by Batlivala & Karani Securities India Private Limited. (Operator Instructions) [...]

Published
2024

19. Q3 2024 Aurobindo Pharma Ltd Earnings Call - Final

Subjects
Aurobindo Pharma Ltd. -- Forecasts and trends, Pharmaceutical industry -- Forecasts and trends, Market trend/market analysis, Business, Revlimid (Medication)
Abstract

Presentation OPERATOR: Welcome to Aurobindo Pharma Q3 FY24 earnings call. Please note that all participant lines will be in listen-only mode and there will be an opportunity for you to [...]

Published
2024

20. Q3 2024 Zydus Lifesciences Ltd Earnings Call - Final

Subjects
Business, Revlimid (Medication), Asacol (Medication)
Abstract

Presentation OPERATOR: Welcome to Zydus Lifesciences Limited Q3 FY24 earnings conference call. (Operator Instructions) Please note that this conference is being recorded. I now hand the conference over to Mr. [...]

Published
2024

21. Q4 2023 BristolMyers Squibb Co Earnings Call - Final

Subjects
Bristol-Myers Squibb Co., Pharmaceutical industry, Business, Camzyos (Medication), Revlimid (Medication), Reblozyl (Medication), Zeposia (Medication), Opdivo (Medication), Opdualag (Medication), Sotyktu (Medication)
Abstract

Presentation OPERATOR: Welcome to the Bristol-Myers Squibb Fourth Quarter 2023 Earnings Conference Call. (Operator Instructions) Please note, this event is being recorded. I would now like to turn the conference [...]

Published
2024

22. Q3 2024 Dr Reddy's Laboratories Ltd Earnings Call - Final

Subjects
United States. Food and Drug Administration, Dr. Reddy's Laboratories Ltd., Financial statements, Pharmaceutical industry, Business, Revlimid (Medication)
Abstract

Presentation OPERATOR: Ladies and gentlemen, good day, and welcome to the Dr. Reddy's Q3 FY '24 Earnings Conference Call. (Operator Instructions) Please note that this conference is being recorded. I [...]

Published
2024

23. Q2 2024 Natco Pharma Ltd Earnings Call - Final

Subjects
Natco Pharma Ltd. -- International economic relations, Pharmaceutical industry -- International economic relations, Business, Revlimid (Medication)
Abstract

Presentation OPERATOR: Ladies and gentlemen, good day and welcome to the Natco Pharma Limited Q2 FY '24 Earnings Conference Call, hosted by Batlivala & Karani Securities India Pvt. Ltd. (Operator [...]

Published
2023

24. Q2 2024 Aurobindo Pharma Ltd Earnings Call - Final

Subjects
Market trend/market analysis, Business, Revlimid (Medication)
Abstract

Presentation OPERATOR: Welcome to Aurobindo Pharma Q2 FY '24 Earnings Call. (Operator Instructions) Please note that this conference is being recorded. I now hand the conference over to management for [...]

Published
2023

25. Q2 2024 Aurobindo Pharma Ltd Earnings Call - Final

Subjects
Market trend/market analysis, Business, Revlimid (Medication)
Abstract

Presentation OPERATOR: Welcome to Aurobindo Pharma Q2 FY'24 Earnings Call. (Operator Instructions) Please note that this conference is being recorded. I now hand the conference over to management for opening [...]

Published
2023

26. Q2 2024 Zydus Lifesciences Ltd Earnings Call - Final

Subjects
Executives, Business, Revlimid (Medication)
Abstract

Presentation GANESH NARAYAN NAYAK, COO & EXECUTIVE DIRECTOR, ZYDUS LIFESCIENCES LIMITED: (technical difficulty) For today's call we have Dr. Sharvil Patel Managing Director; Mr. Nitin Parekh, Chief Financial Officer; Mr. [...]

Published
2023

28. Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2023

Subjects
United States. Food and Drug Administration, General interest, News, opinion and commentary, Revlimid (Medication), Yervoy (Medication), Reblozyl (Medication), Opdivo (Medication)
Abstract

PRINCETON: Bristol Myers Squibb has issued the following news release: Bristol Myers Squibb (NYSE: BMY) today reports results for the fourth quarter and full year of 2023, which reflect strong [...]

Published
2024

29. Bristol-Myers Squibb clocks 1% YoY revenue growth in Q4

Subjects
Bristol-Myers Squibb Co. -- Company sales and earnings, Pharmaceutical industry -- Company sales and earnings, Company earnings/profit, General interest, News, opinion and commentary, Revlimid (Medication), Opdivo (Medication)
Abstract

Bristol-Myers Squibb Company BMY said that its fourth-quarter revenues were $11.48 billion, up 1% Y/Y, beating the consensus estimate of $11.19 billion, driven primarily by higher sales of a new [...]

Published
2024

30. Half Year 2024 Cipla Ltd Earnings Call - Final

Subjects
United States. Food and Drug Administration, Cipla Ltd., Pharmaceutical industry, Business, Revlimid (Medication)
Abstract

Presentation OPERATOR: Ladies and gentlemen, good day, and welcome to Cipla Limited Conference Call. (Operator Instructions) Please note that this conference is being recorded. I now hand the conference over [...]

Published
2023

31. Half Year 2024 Dr Reddy's Laboratories Ltd Earnings Call - Final

Subjects
Dr. Reddy's Laboratories Ltd., Financial statements, Business, Revlimid (Medication)
Abstract

Presentation OPERATOR: Ladies and gentlemen, good day, and welcome to the Dr. Reddy's Q2 FY '24 Earnings Conference Call. (Operator Instructions) Please note that this conference is being recorded. I [...]

Published
2023

32. Half Year 2024 Cipla Ltd Earnings Call - Final

Subjects
United States. Food and Drug Administration, Cipla Ltd., Pharmaceutical industry, Business, Revlimid (Medication)
Abstract

Presentation OPERATOR: Ladies and gentlemen, good day, and welcome to Cipla Limited Conference Call. (Operator Instructions) Please note that this conference is being recorded. I now hand the conference over [...]

Published
2023

33. Event Brief of Q3 2023 Bristol-Myers Squibb Co Earnings Call - Final

Subjects
Bristol-Myers Squibb Co. -- Conferences, meetings and seminars, Citigroup Inc. -- Conferences, meetings and seminars, Financial services industry -- Conferences, meetings and seminars, Chairpersons -- Conferences, meetings and seminars, Pharmaceutical industry -- Conferences, meetings and seminars, Financial services industry, Business, Camzyos (Medication), Revlimid (Medication), Reblozyl (Medication), Zeposia (Medication), Krazati (Medication), Opdivo (Medication), Opdualag (Medication), Sotyktu (Medication)
Abstract

CORPORATE PARTICIPANTS . Adam Lenkowsky - Bristol-Myers Squibb Company,Executive VP, Chief Commercialization Officer & Head of U.S. Oncology . Christopher S. Boerner - Bristol-Myers Squibb Company,Executive VP, COO & Director [...]

Published
2023

34. Q3 2023 BristolMyers Squibb Co Earnings Call - Final

Subjects
Bristol-Myers Squibb Co., Chief operating officers, Pharmaceutical industry, Business, Camzyos (Medication), Revlimid (Medication), Reblozyl (Medication), Zeposia (Medication), Krazati (Medication), Opdivo (Medication), Opdualag (Medication), Sotyktu (Medication)
Abstract

Presentation OPERATOR: Hello, and welcome to the Bristol-Myers Squibb's Third Quarter 2023 Earning Earnings Conference Call. (Operator Instructions) Please note, this event is being recorded. I would now like to [...]

Published
2023

35. Q4 2023 Torrent Pharmaceuticals Ltd Earnings Call - Final

Subjects
Torrent Pharmaceuticals Ltd., Pharmaceutical industry, Business, Revlimid (Medication)
Abstract

Presentation OPERATOR: Ladies and gentlemen, good day, and welcome to the Q4 FY '23 Earnings Conference Call of Torrent Pharmaceuticals Limited. (Operator Instructions) Please note that this conference is being [...]

Published
2023

36. Q4 2023 Natco Pharma Ltd Earnings Call - Final

Subjects
Natco Pharma Ltd., Pharmaceutical industry, Business, Revlimid (Medication)
Abstract

Presentation OPERATOR: Ladies and gentlemen, good day, and welcome to the Q4 FY '23 earnings conference call of NATCO Pharma Limited Hosted line Nuvama Wealth Management. (Operator Instructions) Please note [...]

Published
2023

37. Q4 2023 Aurobindo Pharma Ltd Earnings Call - Final

Subjects
United States. Food and Drug Administration -- Officials and employees, Aurobindo Pharma Ltd., Pharmaceutical industry -- Officials and employees, Business, Revlimid (Medication)
Abstract

Presentation OPERATOR: Good morning, and welcome to Aurobindo Pharma Quarter 4 FY '23 Earnings Call. (Operator Instructions) Please note that this conference is being recorded. I now hand the conference [...]

Published
2023

38. Q4 2023 Zydus Lifesciences Ltd Earnings Call - Final

Subjects
United States. Food and Drug Administration, Executives, Financial markets, Business, Revlimid (Medication), Asacol (Medication)
Abstract

Presentation GANESH NARAYAN NAYAK, COO & EXECUTIVE DIRECTOR, ZYDUS LIFESCIENCES LIMITED: Good evening, ladies and gentlemen. Welcome to our post results teleconference for the fourth quarter and the financial year [...]

Published
2023

39. Full Year 2023 Cipla Ltd Earnings Call - Final

Subjects
Cipla Ltd. -- Company sales and earnings, Pharmaceutical industry -- Company sales and earnings, Company earnings/profit, Business, Revlimid (Medication), Advair Diskus (Medication)
Abstract

Presentation OPERATOR: Ladies and gentlemen, good day, and welcome to the Cipla Limited Q4 FY '23 Earnings Conference Call. We've been joined by Mr. Umang Vohra, MD and Global CEO, [...]

Published
2023

40. Revlimid: Claims against Dr Reddy’s in US court dismissed

Subjects
Antitrust law, Multiple myeloma, Antitrust issue, News, opinion and commentary, Revlimid (Medication)
Abstract

December 29 -- Dr Reddy’s Laboratories on Thursday said all claims against the company in an antitrust litigation related to a prescription medicine, Revlimid, filed in a US court have [...]

Published
2022

41. Starton Therapeutics notifies safety signals with STAR-LLD in patients of myeloma

Subjects
Multiple myeloma -- Safety and security measures, General interest, News, opinion and commentary, Revlimid (Medication)
Abstract

PARAMUS: Starton Therapeutics Inc. ('Starton' or the 'Company'), a clinical stage biotechnology company transforming standard of care therapies with proprietary dermal technologies, announced today initial key safety and efficacy signals [...]

Published
2024

44. Event Brief of Q1 2023 Bristol-Myers Squibb Co Earnings Call - Final

Subjects
The Goldman Sachs Group Inc. -- Officials and employees -- Conferences, meetings and seminars, Bristol-Myers Squibb Co. -- Officials and employees -- Conferences, meetings and seminars, Citigroup Inc. -- Conferences, meetings and seminars -- Officials and employees, Financial services industry -- Officials and employees -- Conferences, meetings and seminars, Investment banks -- Officials and employees -- Conferences, meetings and seminars, Chairpersons -- Conferences, meetings and seminars, Pharmaceutical industry -- Conferences, meetings and seminars -- Officials and employees, Financial services industry, Business, Revlimid (Medication), Opdivo (Medication), Opdualag (Medication), Sotyktu (Medication)
Abstract

CORPORATE PARTICIPANTS . Christopher S. Boerner - Bristol-Myers Squibb Company,Executive VP & Chief Commercialization Officer . David V. Elkins - Bristol-Myers Squibb Company,Executive VP & CFO . Giovanni Caforio - [...]

Published
2023

45. Q1 2023 BristolMyers Squibb Co Earnings Call - Final

Subjects
Bristol-Myers Squibb Co. -- Officials and employees, Pharmaceutical industry -- Officials and employees, Business, Revlimid (Medication), Reblozyl (Medication), Opdivo (Medication), Opdualag (Medication), Sotyktu (Medication)
Abstract

Presentation OPERATOR: Good day, and welcome to the Bristol-Myers Squibb First Quarter 2023 Earnings Call. (Operator Instructions) And finally, I would like to advise all participants that this call is [...]

Published
2023

46. Q3 2023 Natco Pharma Ltd Earnings Call - Final

Subjects
Natco Pharma Ltd. -- International economic relations, Pharmaceutical industry -- International economic relations, Business, Revlimid (Medication)
Abstract

Presentation OPERATOR: Ladies and gentlemen, good day and welcome to NATCO Pharma Limited Q3 FY '23 Earnings Conference Call hosted by Nuvama Wealth. (Operator Instructions) Please note that this conference [...]

Published
2023

47. BristolMyers Squibb Co at Guggenheim Healthcare Talks Oncology Day - Final

Subjects
Bristol-Myers Squibb Co., Biological products, Health care industry, Pharmaceutical industry, Health care industry, Business, Revlimid (Medication), Opdivo (Medication), Opdualag (Medication)
Abstract

Presentation SEAMUS CHRISTOPHER FERNANDEZ, SENIOR ANALYST OF GLOBAL PHARMACEUTICALS, GUGGENHEIM SECURITIES, LLC, RESEARCH DIVISION: Okay. Good afternoon, everybody. Thanks for joining us for today's fireside chat discussion with Bristol-Myers Squibb. [...]

Published
2023

48. Event Brief of Q4 2022 Bristol-Myers Squibb Co Earnings Call - Final

Subjects
The Goldman Sachs Group Inc. -- Officials and employees -- Conferences, meetings and seminars, Bristol-Myers Squibb Co. -- Officials and employees -- Conferences, meetings and seminars, Citigroup Inc. -- Conferences, meetings and seminars -- Officials and employees, Financial services industry -- Officials and employees -- Conferences, meetings and seminars, Investment banks -- Officials and employees -- Conferences, meetings and seminars, Chairpersons -- Conferences, meetings and seminars, Pharmaceutical industry -- Conferences, meetings and seminars -- Officials and employees, Financial services industry, Business, Revlimid (Medication), Reblozyl (Medication), Sotyktu (Medication)
Abstract

CORPORATE PARTICIPANTS . Christopher S. Boerner - Bristol-Myers Squibb Company,Executive VP & Chief Commercialization Officer . David V. Elkins - Bristol-Myers Squibb Company,Executive VP & CFO . Giovanni Caforio - [...]

Published
2023

49. Q4 2022 BristolMyers Squibb Co Earnings Call - Final

Subjects
Bristol-Myers Squibb Co. -- Officials and employees, Pharmaceutical industry -- Officials and employees, Business, Revlimid (Medication), Reblozyl (Medication), Sotyktu (Medication)
Abstract

Presentation OPERATOR: Good morning. My name is Dennis, and I will be your conference operator today. At this time, I would like to welcome everyone to the Bristol-Myers Squibb Fourth [...]

Published
2023

50. Q3 2023 Cipla Ltd Earnings Call - Final

Subjects
United States. Food and Drug Administration, Cipla Ltd., Pharmaceutical industry, Business, Revlimid (Medication), Advair Diskus (Medication)
Abstract

Presentation OPERATOR: Ladies and gentlemen, good day, and welcome to Cipla Limited Q3 FY '23 Earnings Conference Call. (Operator Instructions) Please note that this conference is being recorded. I now [...]

Published
2023

Catalog

Books, media, physical & digital resources
See catalog results